Captor Therapeutics ® Investor Relations

      Investor Relations

      Progress in research and development related to CT-01 project

      Publication date: 2022-01-11
      Number: RB ESPI 3/2022

      Current Report No. 3/2022

      Date of preparation: 11 January 2022

      Subject: Progress in research and development related to CT-01 project 

      Legal basis: Art. 17(1) of MAR – inside information

      The Management Board of Captor Therapeutics S.A., with its registered office in Wrocław ("Company") hereby announces significant scientific progress in the CT-01 project which is focused on the development of targeted protein degradation therapy for hepatocellular carcinoma.

      The Company obtained preclinical proof-of-concept data that confirm the potent antitumor activity of two CT-01 lead compounds in a liver cancer mouse xenograft model. These new results demonstrate that oral administration of these CT-01 candidates results in tumour regression in a Hep 3B2.1-7 mouse model of hepatocellular carcinoma.

      This preclinical data represents a significant milestone and supports the further advancement of the Captor’s candidates towards IND-enabling studies. Simultaneously, these results demonstrate the capability of the Company to rationally discover and optimise molecular glue-type degraders using its OptigradeTM platform.

      The Company will inform about further progress in CT-01 project in accordance with legal requirements.